Table 1.
Patient and Visit Characteristics for Outpatient Encounters in a General Dermatologic Practice, Excluding Mohs Surgeonsa
| Characteristic | No. (%) | P valuec | ||||
|---|---|---|---|---|---|---|
| Total | White | Black | Asian | Other racesb | ||
| Encounters | ||||||
| All | 66 463 (100) | 46 575 (70.1) | 16 273 (24.5) | 2831 (4.3) | 784 (1.2) | NA |
| Female patients | 39 598 (59.6) | 25 843 (65.3) | 11 642 (29.4) | 1635 (4.1) | 478 (1.2) | <.001 |
| Male patients | 26 865 (40.4) | 20 732 (77.2) | 4631 (17.2) | 1196 (4.5) | 306 (1.1) | <.001 |
| Age, mean (SD), y | 55.9 (18.5) | 58.0 (18.4) | 52.5 (17.6) | 44.4 (18.2) | 44.1 (16.9) | <.001 |
| Per encounter, mean (SD) | ||||||
| wRVUs | 1.40 (0.71) | 1.50 (0.74) | 1.18 (0.55) | 1.19 (0.60) | 1.22 (0.53) | <.001 |
| Net payments, $ | 133.39 (112.74) | 145.57 (119.81) | 103.02 (86.53) | 111.46 (92.78) | 119.24 (92.11) | <.001 |
| Insurance typed | ||||||
| Commercial | 51 490 (77.5) | 37 595 (80.7) | 10 745 (66.0) | 2479 (87.6) | 671 (85.6) | <.001 |
| Medicare | 22 942 (34.5) | 16 702 (35.9) | 5751 (35.3) | 391 (13.8) | 98 (12.5) | <.001 |
| Medicaid | 1494 (2.3) | 528 (1.1) | 887 (5.5) | 44 (1.6) | 35 (1.2) | <.001 |
| Self-pay | 697 (1.1) | 442 (1.0) | 196 (1.2) | 40 (1.4) | 19 (2.4) | <.001 |
| Othere | 1210 (1.8) | 826 (1.8) | 328 (2.0) | 46 (1.6) | 10 (1.3) | .11 |
| Encounter diagnoses | ||||||
| AK | 10 169 (15.3) | 10 102 (21.7) | 29 (0.2) | 8 (0.3) | 30 (3.8) | <.001 |
| Neoplasm of uncertain behavior | 10 638 (16.0) | 9460 (20.3) | 907 (5.6) | 207 (7.3) | 64 (8.2) | <.001 |
| BCC | 413 (0.6) | 403 (0.9) | 8 (0.1) | 1 (0.0) | 1 (0.1) | <.001 |
| SCC | 243 (0.4) | 230 (0.5) | 12 (0.1) | 1 (0.0) | 0 | <.001 |
| SCC in situ | 111 (0.2) | 101 (0.2) | 9 (0.1) | 1 (0.0) | 0) | <.001 |
| Melanoma | 210 (0.3) | 194 (0.4) | 10 (0.1) | 6 (0.2) | 0 | <.001 |
| Other malignant neoplasm | 51 (0.1) | 33 (0.1) | 18 (0.1) | 0 | 0 | .14 |
| Any skin cancerf | 902 (1.4) | 845 (1.8) | 48 (0.3) | 8 (0.3) | 1 (0.1) | <.001 |
| Procedures rendered | ||||||
| Premalignant lesion destruction | 8092 (12.2) | 8044 (17.3) | 23 (0.1) | 7 (0.3) | 18 (2.3) | <.001 |
| Biopsy | 10 935 (16.5) | 9335 (20.0) | 1267 (7.8) | 260 (9.2) | 73 (9.3) | <.001 |
| Malignant lesion destruction | 243 (0.4) | 238 (0.5) | 4 (0.0) | 1 (0.0) | 0 | <.001 |
| Malignant excision | 228 (0.3) | 223 (0.5) | 4 (0.0) | 0 | 1 (0.1) | <.001 |
| Benign excision | 279 (0.4) | 189 (0.4) | 82 (0.5) | 8 (0.3) | 0 | .06 |
Abbreviations: AK, actinic keratosis; BCC, basal cell carcinoma; NA, not applicable; wRVUs, work relative value units; SCC, squamous cell carcinoma.
All characteristics in this table were analyzed at the encounter level and not at the patient level.
Other races included American Indian or Native American, Native Hawaiian or Other Pacific Islander, and multiple races.
P values for continuous variables were calculated by 1-way analysis of variance. P values for categorical variables were calculated by χ2 test of independence or Fisher exact test.
Totals for insurance type exceeded the total number of encounters in the cohort because more than 1 insurance type was billed in some encounters.
Other insurance types were predominantly government-sponsored insurance programs.
Any skin cancer included BCC, SCC, melanoma, and other malignant neoplasms of the skin.